NCT06078787View on ClinicalTrials.gov

Olaparib in PALB2 Advanced Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2026

Conditions
Advanced Pancreatic CancerMetastatic Pancreatic Cancer
Interventions
DRUG

Olaparib 150 MG

Olaparib should be dosed 2 x 150 mg tablets (300 BID)

Trial Locations (1)

41125

RECRUITING

Aou Modena, Modena

All Listed Sponsors
lead

Azienda Ospedaliero-Universitaria di Modena

OTHER